Program
TD001
A development code.
Its studies are mostly in Prostatic Neoplasms, Castration-Resistant, led by T.O.A.D. Oncology.
Furthest: phase 2, since Nov 20, 20251 company-led study, 1 open or runningNext primary completion: Mar 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| T.O.A.D. Oncology | 11 open or running | phase 2since Nov 20, 2025 | Nov 20, 2025 | Mar 2028phase 2 · NCT07258407 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2025First study: phase 2 study in Prostatic Neoplasms, Castration-ResistantFirst studyNCT07258407 · 180 planned · United States, Australia, Canada and more
Ahead
- Mar 2028Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT07258407
TargetBeta
FOLH1 →read by rule
“This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).”study text, by rule · the study
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07258407Prostatic Neoplasms, Castration-Resistant · United States, Australia, Canada and more | 2 | Recruiting | Mar 2028 | 180 |
How it is read
Names in the registry
- “TD001”, 1 entry
Codes read as this program: TD001.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.